For decades, the standard emergency treatment for anaphylaxis — the sudden, life-threatening whole-body allergic reaction triggered by insect stings, foods, medications, latex, and other allergens — has been epinephrine administered by intramuscular injection, typically delivered by the patient or a bystander using an EpiPen or similar autoinjector. Epinephrine is highly effective and saves lives. The autoinjector device has been available for over 40 years.
And yet, study after study has documented the same alarming finding: people who need epinephrine during anaphylaxis — and who have an autoinjector prescribed and physically available — often do not use it in time. Fear of needles, anxiety about self-injection, hesitation about whether the reaction is "severe enough" to warrant the shot, and the physical complexity of operating the device under panic conditions all contribute to delayed epinephrine administration — and delay is a primary driver of anaphylaxis deaths.
Neffy, an epinephrine nasal spray developed by ARS Pharmaceuticals and approved by the FDA in August 2024, directly addresses that barrier. Neffy delivers epinephrine through the nasal mucosa — the highly vascular membrane lining of the nasal passages — without a needle, without a device requiring assembly, and without the injection step that paralyzes many anaphylaxis patients in their most critical moments. The product looks like a standard nasal spray, fits in a pocket or a purse easily, and requires only that the patient or a bystander insert the nozzle into one nostril and press. In pharmacokinetic studies, neffy achieved epinephrine blood concentrations comparable to intramuscular injection within a clinically relevant timeframe.
The Data Behind Neffy's Approval and Real-World Promise
The FDA approval of neffy was supported by three Phase 3 pharmacokinetic studies demonstrating bioequivalence to epinephrine autoinjectors under conditions of nasal decongestion (the most common barrier to nasal drug delivery during allergic reactions, when nasal blood vessel swelling might theoretically reduce absorption). The studies showed that neffy achieved epinephrine plasma concentrations consistent with the pharmacokinetic profile established for intramuscular injection — including under conditions of exercise-induced and antihistamine-induced nasal effects.
Clinical allergy professionals have noted that neffy's introduction creates a genuinely new option for the patients most likely to delay treatment: children old enough to self-administer, adults with needle phobia, caregivers who are hesitant to inject someone else, and patients whose anaphylaxis protocol has always required a third party to be present for injection. The availability of a device-free option reduces the dependency on trained personnel for initial epinephrine administration — a dependency that has contributed to deaths in settings where trained staff or willing bystanders were not immediately available.
With an estimated 32 million Americans having food allergies, approximately 6 million having insect venom allergies, and over 1.6 million experiencing anaphylaxis annually, the potential population benefiting from an easier-to-use epinephrine option is enormous. Schools, summer camps, recreational facilities, and workplaces that have historically resisted stocking epinephrine autoinjectors due to the training burden can more readily maintain neffy as an accessible emergency resource.
Summer 2026 Makes This Story Particularly Timely
Summer is peak anaphylaxis season in the United States. Insect stings — from bees, wasps, yellow jackets, and hornets — are the leading cause of summer anaphylaxis, accounting for more than 90 deaths annually. Outdoor dining, summer camps, food festivals, and cookouts increase exposure to food allergens in settings where autoinjectors may not be immediately available or where hesitation about injection is highest. The awareness that a needle-free nasal spray option now exists — and is available by prescription — is directly actionable for the millions of Americans managing life-threatening allergies during the most exposure-intensive months of the year.
Patients with anaphylaxis prescriptions should discuss neffy with their allergist or physician. Neffy is available by prescription and is covered by many insurance plans. It is approved for adults and pediatric patients weighing at least 30 kilograms (approximately 66 pounds). Carrying two doses is recommended (as with autoinjectors) in case a second dose is needed before emergency services arrive.
Frequently Asked Questions
Q: What is neffy and when was it approved?
A: Neffy is a single-dose epinephrine nasal spray for the emergency treatment of Type 1 allergic reactions, including anaphylaxis. It was FDA-approved in August 2024 and is now in real-world clinical use in 2026.
Q: How does neffy work compared to an EpiPen?
A: Both deliver epinephrine — the first-line treatment for anaphylaxis. Neffy delivers it through the nasal mucosa rather than by intramuscular injection. Clinical studies show comparable blood concentration profiles to autoinjectors.
Q: Who can use neffy?
A: Adults and pediatric patients weighing at least 30 kilograms (approximately 66 pounds). It is available by prescription from an allergist or primary care physician.
Q: Why is needle-free epinephrine a significant advance?
A: Studies consistently show that patients with anaphylaxis prescriptions frequently delay or fail to use autoinjectors due to needle fear, hesitation, and complexity under panic conditions. A needle-free nasal spray removes these barriers, which may save lives through faster treatment initiation.
Q: Can neffy replace an EpiPen in all situations?
A: Neffy is approved as a first-line treatment for anaphylaxis, equivalent in indication to autoinjectors. Patients should carry two doses and should still call 911 after any anaphylaxis event, even if epinephrine was administered.
